# US 2019/0315810 A1 · Flagellin-based agents and uses including effective vaccination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315810 A1
- Document ID: US20190315810A1
- Status: Published application
- Kind: A1
- Application number: 16/414,403
- Filed: 2019-05-16
- Published: 2019-10-17
- Earliest claimed: 2014-07-30
- Assignees: Genome Protection, Inc.
- Applicants: Genome Protection, Inc.
- Inventors: Andrei V. GUDKOV; Vadim METT; Vadim KRIVOKRYSENKO
- Web page: https://patentgrep.com/patent/US20190315810A1

## CPC

- C07K 14/195: from bacteria
- A61K 38/164: {from bacteria}
- A61K 39/0013: {Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine}
- A61K 39/02: Bacterial antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55583: {Polysaccharides}
- A61K 2039/55594: {from bacteria}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to, in part, compositions comprising improved flagellin derived constructs and methods of using for vaccination, including adjuvants comprising flagellin-based agents.

## Claims

### Claim 1

A vaccine composition, comprising
(a) an adjuvant comprising a flagellin-based agent, or variants thereof having TLR5 agonist activity and an aluminum gel or salt and
(b) an antigen.

### Claim 2 (depends on 1)

The vaccine of claim 1, wherein the vaccine causes a relative increase in a titer of at least 1, at least 2, at least 3, or all of IgG1, IgG2a, IgG2b, and IgG3 antibodies as compared to the vaccine in the absence of the flagellin-based agent.

### Claim 3 (depends on 1, 2)

The vaccine of any one of claims 1-2, wherein the flagellin-based agent comprises an amino acid sequence of one or more of the sequences in Table 1, or variants thereof having TLR5 agonist activity.

### Claim 4 (depends on 1, 2, 3)

The vaccine of any one of claims 1-3, wherein the flagellin-based agent comprises an amino acid sequence having at least 80% identity, or at least 85% identity, or at least 90% identity, or at least 95% identity, or at least 97% identity, or at least 98% identity, or at least 99% identity with one or more of SEQ ID Nos.: 1-252.

### Claim 5 (depends on 1)

The vaccine of claim 1, wherein the flagellin-based agent is a variant of SEQ ID NO: 1.

### Claim 6 (depends on 1)

The vaccine of claim 1, wherein the flagellin-based agent comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The vaccine of any one of claims 1-6, wherein the flagellin-based agent is a variant of CBLB 502 (i.e. an amino acid sequence of SEQ ID NO: 2).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The vaccine of any one of claims 1-7, wherein the flagellin-based agent comprises an amino acid sequence having at least 80% identity, or at least 85% identity, or at least 90% identity, or at least 95% identity, or at least 97% identity, or at least 98% identity, or at least 99% identity with one or more sequences in Table 1.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The vaccine of any one of claims 1-8, wherein the flagellin-based agent comprises an amino acid sequence having at least 80% identity, or at least 85% identity, or at least 90% identity, or at least 95% identity, or at least 97% identity, or at least 98% identity, or at least 99% identity with one or more of CBLB502-S33ML (SEQ ID NO: 35), CBLB502-485CT (CBLB533, SEQ ID NO: 71), and CBLB502-S33MX (SEQ ID NO: 150).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The vaccine of any one of claims 1-9, wherein the flagellin-based agent is a flagellin derivative from a thermophilic microorganism, optionally selected from SEQ ID NOs: 243-252.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The vaccine of any one of claims 1-10, wherein the flagellin-based agent is a flagellin derivative from a microorganism well-tolerated by human, optionally selected from SEQ ID NOs: 243-252.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The vaccine of any one of claims 1-11, wherein the flagellin-based agent comprises an amino acid sequence having at least 80% identity, or at least 85% identity, or at least 90% identity, or at least 95% identity, or at least 97% identity, or at least 98% identity, or at least 99% identity with one or more of SEQ ID NOs: 243-252.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The vaccine of any one of claims 1-12, wherein the aluminum gel or salt is selected from aluminum hydroxide, aluminum phosphate, and potassium aluminum sulfate, AS04, and ALHYDROGEL.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The vaccine of any one of claims 1-13, wherein the vaccine comprises any one of the adjuvants or antigens annotated in the VIOLIN database.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The vaccine of any one of claims 1-14, wherein the antigen is that of one or more of the following vaccines: DTP (diphtheria-tetanus-pertussis vaccine), DTaP (diphtheria-tetanus-acellular pertussis vaccine), Hib (Haemophilus influenzae type b) conjugate vaccines, Pneumococcal conjugate vaccine, Hepatitis A vaccines, Poliomyelitis vaccines, Yellow fever vaccines, Hepatitis B vaccines, combination DTaP, Tdap, Hib, Human Papillomavirus (HPV) vaccine, Anthrax vaccine, and Rabies vaccine.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The vaccine of any one of claims 1-15, wherein the vaccine further comprises an additional adjuvant selected from oil-in-water emulsion formulations, saponin adjuvants, ovalbumin, Freunds Adjuvants, cytokines, and chitosans.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The vaccine of any one of claims 1-16, wherein one or more of the flagellin-based agent and antigen are adsorbed to the aluminum gel or salt.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The vaccine of any one of claims 1-17, wherein the flagellin-based agent and aluminum gel or salt are mixed to form a stable complex.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The vaccine of any one of claims 1-18, wherein the flagellin-based agent and aluminum gel or salt are mixed in a ratio (w/w) of about 1:500 or less.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The vaccine of any one of claims 1-19, wherein the flagellin-based agent and aluminum gel or salt are mixed in a ratio (w/w) of about 1:500, or about 1:600, or about 1:700, or about 1:800, or about 1:900, or about 1:1000, or about 1:2000, or about 1:5000, or about 1:10000.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The vaccine of any one of claims 1-20, wherein the flagellin-based agent and aluminum gel or salt are mixed in a ratio that is substantially below a loading capacity of the aluminum salt.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The vaccine of any one of claims 1-21, wherein the vaccine causes an improvement in adjuvant properties relative to a vaccine comprising the antigen and the aluminum gel or salt alone.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The vaccine of any one of claims 1-22, wherein the vaccine and/or adjuvant causes immunostimulation of one or more of TH1 and TH2-mediated immune response.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The vaccine of any one of claims 1-23, wherein the vaccine and/or adjuvant causes immunostimulation of TH1-mediated immune response at levels greater than a vaccine comprising the antigen and the aluminum gel or salt alone.

### Claim 25

A method of vaccinating a subject against a disorder, comprising administering an effective amount of a vaccine comprising:
(a) an adjuvant comprising a flagellin-based agent, or variants thereof having TLR5 agonist activity and an aluminum gel or salt and
(b) an antigen associated with the disorder.

### Claim 26 (depends on 25)

The method of claim 25, wherein the disorder is selected from infectious diseases, cancers, and allergies.

### Claim 27 (depends on 25, 26)

The method of any one of claims 25-26, wherein the disorder is selected from diphtheria, tetanus, pertussis, influenza, pneumonia, hepatitis A, hepatitis B, polio, yellow fever, Human Papillomavirus (HPV) infection, anthrax, rabies, Japanese Encephalitis, meningitis, measles, mumps, rubella, gastroenteritis, smallpox, typhoid fever, varicella (chickenpox), rotavirus, and shingles.

### Claim 28 (depends on 25, 26, 27)

The method of any one of claims 25-27, wherein the antigen is administered simultaneously with or sequentially to the adjuvant.

### Claim 29 (depends on 25, 26, 27, 28)

The method of any one of claims 25-28, wherein the flagellin-based agent comprises the amino sequence of SEQ ID No: 2.

### Claim 30

A method of immunostimulating a subject in advance of or concurrent with vaccination, comprising administering an effective amount of an adjuvant comprising a flagellin-based agent, or variants thereof having TLR5 agonist activity and an aluminum gel or salt, wherein both TH1 and TH2-mediated immune responses are immunostimulated.

### Claim 31 (depends on 29)

The method of claim 29, wherein the disorder is selected from infectious diseases, cancers, and allergies.

### Claim 32 (depends on 29, 30)

The method of claim 29 or 30, wherein the vaccination is for a disorder selected from diphtheria, tetanus, pertussis, influenza, pneumonia, hepatitis A, hepatitis B, polio, yellow fever, Human Papillomavirus (HPV) infection, anthrax, rabies, Japanese Encephalitis, meningitis, measles, mumps, rubella, gastroenteritis, smallpox, typhoid fever, varicella (chickenpox), rotavirus, and shingles.

### Claim 33 (depends on 30, 31, 32)

The method of any one of claims 30-32, wherein the flagellin-based agent comprises the amino sequence of SEQ ID No: 2.
